3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow AR-12286 Ophthalmic Solution 0.5%: new trials by email Literature Review of AR-12286 Ophthalmic Solution 0.5% trials Research Report on AR-12286 Ophthalmic Solution 0.5%
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days PG286 Ophthalmic Solution 0.5%, AR-12286 Ophthalmic Solution 0.5%, Travoprost Ophthalmic Solution 0.004% - Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Aerie Pharmaceuticals | 234 | 2013-02-01 | 2014-03-17 |
| A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months AR-12286 Ophthalmic Solution 0.7%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5% - Ocular Hypertension, Open-angle Glaucoma | Phase 2 | Completed | Aerie Pharmaceuticals | 211 | 2012-10-01 | 2023-08-22 |
| AR-12286 in Combination With Latanoprost Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5% - Glaucoma, Ocular Hypertension | Phase 2 | Completed | Aerie Pharmaceuticals | 66 | 2011-02-01 | 2014-05-08 |
Glaucoma (3) · Ocular Hypertension (3) · Glaucoma, Open-Angle (2)
United States (2)
Brian Levy, OD (1)